GlassScriptPhysician profile
Christopher Zulawski
NPI 1790848489
$8,107.84
in general payments reported to CMS, 2019-2025
48 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,017 · 2022: $1,947 · 2023: $1,873 · 2024: $1,884 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,144.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,482.50 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $619.68 | 2021-2025 | Ajovy, Austedo Xr |
| Pfizer INC. | $582.20 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $530.69 | 2021-2025 | Rytary, Crexont |
| Sk Life Science, INC. | $513.39 | 2021-2025 | |
| Ucb, INC. | $394.00 | 2021-2024 | Briviact, Nayzilam |
| Mdd US Operations, LLC | $321.31 | 2021-2025 | Gocovri, Gocovri, Apokyn |
| Neurelis, INC. | $317.14 | 2021-2025 | Valtoco |
| Lundbeck LLC | $293.81 | 2023-2025 | Vyepti, Rexulti |
| Otsuka America Pharmaceutical, INC. | $284.20 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $271.30 | 2022-2025 | Kisunla, Amyvid, Reyvow |
| Kyowa Kirin, INC. | $245.06 | 2021-2024 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $214.66 | 2022 | |
| Impel Pharmaceuticals INC. | $213.70 | 2022-2023 | Trudhesa |
| Eisai INC. | $183.31 | 2021-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Zulawski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.